Delivery Order SPE2DB24D2109-SPE2DB25FHXTX
- Not listed
- The Defense Logistics Agency awarded a $5,863.86 delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion date of August 21, 2025. The product will be delivered to the contractor's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a ceiling value of $2,108.70. This competitively awarded, non-set-aside contract represents a firm fixed price delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The place of performance is...
- AmerisourceBergen Drug Corp was awarded a delivery order contract by the Defense Logistics Agency (DLA) on July 21, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a ceiling value of $1,405.80 and an ultimate completion date of July 22, 2025. This is a firm fixed-price delivery order with no set-aside designation, issued competitively as a child contract under AmerisourceBergen's larger DLA prime vendor contract vehicle. The place of performance is listed as...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency on July 30, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. This is a firm fixed-price, competitively awarded contract with a ceiling value of $1,354.88 and an ultimate completion date of July 31, 2025. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX),...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, valued at $1,150.32. This is a firm fixed price delivery order with an ultimate completion date of July 28, 2025, and represents a non-set-aside competitive award. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, particularly...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $7,007.80 for NovoLog 100 Unit/ML FlexPen 3ML insulin pens on July 21, 2025, with an ultimate completion date of July 22, 2025. This firm fixed-price delivery order represents a competitively awarded, non-set-aside contract for pharmaceutical supply to support federal medical needs. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for military...
- The Defense Logistics Agency awarded a delivery order valued at $1,746.24 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens. This non-set-aside contract was executed on August 11, 2025, with an ultimate completion date of August 12, 2025, and represents a firm fixed price delivery order for pharmaceutical supplies. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order operates under...
- The Defense Logistics Agency Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $5,751.48 for NovoLog 100 Unit/mL FlexPen 3mL insulin pens on July 25, 2025, with an ultimate completion date of July 28, 2025. This firm fixed-price delivery order represents a competitive, non-set-aside award to supply pharmaceutical products supporting federal military and veteran healthcare systems. The work will be performed at AmerisourceBergen's corporate office in...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $8,392.51 for NovoLog 100 Unit/mL FlexPen 3mL insulin pens on July 28, 2025, with completion targeted for July 29, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a small-value pharmaceutical procurement to support federal medical supply requirements. The delivery order is being fulfilled from AmerisourceBergen's place of performance in Conshohocken,...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, received a $9,353.44 firm fixed-price delivery order from the Defense Logistics Agency's Medical Supply Chain on July 21, 2025, for NovoLog 100 Unit/mL FlexPen 3mL insulin pens. The delivery order, which represents a non-competitive set-aside award, is scheduled for completion by July 22, 2025, with performance occurring at the vendor's Conshohocken facility. This delivery order is issued...
- SPE2DB24D2109Indefinite Delivery Contract
- SPE2DB24D2109-SPE2DB25FHXTXDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a ceiling value of $1,824.37. This firm fixed price delivery order, which is not set-aside designated, will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 25, 2025. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (contract SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999.99 million through December 2026 that enables the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, is a critical federal vendor specializing in medical procurement for military and veteran healthcare systems. The company has demonstrated extensive capability in fulfilling DLA procurement requirements through open competition, delivering a diverse portfolio of pharmaceutical products including specialty medications, brand-name and generic drugs, vaccines, and medical supplies across multiple therapeutic domains to support the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.8k | 8/22/25 |